

Finance & Performance Assurance Committee, Key Issues Report	
Report Date: 30 July 2024	Report of: Finance & Performance Assurance Committee
Date of meeting: 30 July 2024	Members: Richard Miner(Chair), Simon Crowther, David Brown, Helen Troalen and Sara Biffen Attendees: Adam Winstanley, Debbie Bryce, Inese Robotham, Hugh Adams & Lisa Mitchell
1	<p>Agenda</p> <p>The Committee considered the following:-</p> <ul style="list-style-type: none"> • Integrated Performance Report • Performance Highlights • Finance Highlights • People Highlights • Finance Report Month 3 • 2024/25 Final Budget setting paper • Board Assurance Framework, Q1 • Update on Modular Build at RSH • Climate Change Group Key Issues Report • Capital Planning Group Key Issues Report • Efficiency & Sustainability Key Issues Report • Finance & Performance Assurance Committee Annual Report 2023-24 • Project LV Generator Ring 3 Works
2a	<p>Alert <i>Matters of concerns, gaps in assurance or key risks to escalate to the Board</i></p> <p>The Finance & Performance Assurance Committee wish to alert the Board:-</p> <ul style="list-style-type: none"> • UEC 4 Hour performance showed marginal improvement but remains below plan. • Elective Recovery Programme, the Trust has received notification to move back to Tier 1 monitoring due to the deterioration in cancer and RTT performance since April 2024. • Operational challenges with Careflow PAS has impacted on the patient cancellations, DNA rates and the accuracy of the waiting list numbers. • Whilst reporting to be on plan at month three, key issues in relation to the delivery of the financial plan are the use of escalation in July which was above funded levels and the lack of activity data available since the cutover to Careflow meaning the performance against the income plan cannot be assessed. Recovery actions are underway on escalation, but the income issue requires the data to be available to be assessed first which is a key priority of the digital, BI and finance teams to resolve in August. It was agreed that the Board should be briefed on estates issues relating to the modular ward build and the low voltage power supply. Immediate risks to clinical care provision with regard to the latter are fully mitigated.
2b	<p>Assurance <i>Positive assurances and highlights of note for the</i></p> <p>The Finance & Performance Assurance Committee wish to assure the Board:-</p>

	<i>Board</i>	<ul style="list-style-type: none"> Recommend the approval of the final 2024/25 Trust revenue budget whilst noting the level of challenge within the plan. Approval of FPACs Annual Report 2023-24 Reduction in the number of patients waiting over 12 hours in A&E Improvement in paediatric performance by 4.9% Action plans for 4-hour performance, frailty and acute medicine were presented to FPAC. These plans detailed key milestones, KPI measures and impact on 4 hour and 12-hour performance. 		
2c	Advise <i>Areas that continue to be reported on and/or where some assurance has been noted/further assurance sought.</i>	The Finance & Performance Assurance Committee wish to advise the Board:- <ul style="list-style-type: none"> Additional support is in place from NHSE for the UEC improvement plan for 6 months Triomic clinic trial commences in August for colorectal urgent suspected cancer, which should reduce the number of patients requiring diagnostic investigations. 		
2d	Actions Significant follow up actions	The Finance & Performance Assurance Committee wish to the action the following:-		
3	Report compiled by	<i>Richard Miner, Non-Executive Director, Chair of Finance & Performance</i>	Minutes available from	<i>Lisa Mitchell</i>